Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derilatives as IP antagonists

本发明涉及通常作为IP受体拮抗剂且由通式(I)所示的化合物，其中G#+[1]选自基团a、b#+[1]和b#+[2]；(式a、b#+[1]和b#+[2])以及A和G#+[2]如说明书中所定义；或其单个的异构体、异构体的外消旋或非外消旋混合物或其可药用盐或溶剂化物。本发明还涉及含有该类化合物的药物组合物、其用作治疗剂的用途及其制备方法。 This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein G1 i...

Full description

Saved in:
Bibliographic Details
Main Authors C. O'YANG, D. NITZAN, F.J. LOPEZ-TAPIA
Format Patent
LanguageChinese
English
Published 08.09.2004
Edition7
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:本发明涉及通常作为IP受体拮抗剂且由通式(I)所示的化合物，其中G#+[1]选自基团a、b#+[1]和b#+[2]；(式a、b#+[1]和b#+[2])以及A和G#+[2]如说明书中所定义；或其单个的异构体、异构体的外消旋或非外消旋混合物或其可药用盐或溶剂化物。本发明还涉及含有该类化合物的药物组合物、其用作治疗剂的用途及其制备方法。 This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein G1 is selected from the group consisting of a, b1 and b2, and A and G2 are as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
Bibliography:Application Number: CN20028005870